The interest in hot stocks today is increasing as retail traders are keen to find good meme stocks. We hope to see a penny stock frenzy similar to the bull run in February of this year.
Many small-cap companies, trading both on OTC and Nasdaq, are ready to expand their operations as the pandemic is relatively under control.
So far, the economic recovery is looking good, although investors are concerned about increasing inflation. Nevertheless, the Federal Reserve says high inflation is only temporary, and it may continue the accommodative monetary policy and keep the pace of the bond-buying program at least until the beginning of next year, despite disappointing labor market data.
On Wednesday, US stocks edged up driven by upbeat factory data. Factory production data showed that manufacturing maintains strong despite a slowdown caused by factory closures related to Hurricane Ida and the ongoing microchip crisis.
Rubeela Farooqi, chief US economist at High Frequency Economics, told Reuters:
“Growth in manufacturing going forward is likely to be supported by low inventories. But supply issues and shortages remain a constraint for now that are preventing a stronger rebound.”
Meanwhile, JPMorgan Securities analyst Marko Kolanovic said that the Delta wave might be slowing down in the US and globally, and the recovery should restart soon.
All in all, this is a great time to invest in hot stocks today and secure big profits that wouldn’t be possible with blue chips.
FINDING OPPORTUNITIES IN HOT STOCKS TODAY
There are plenty of opportunities for investors if they follow us here at Insider Financial.
We preach the key to trading hot stocks is finding the momentum BEFORE it happens and then be patient. Now, when we say that we find the momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.
We always alert our subscribers first before we publish for our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here. We alert our subscribers with our best ideas before our regular readers.
Subscribers got in TSNP/HMBL at $.027, which you can read here.
ENZC at $.014, which you can read here.
MRNA at $23, which you can read here.
ALPP at $.075, which you can read here.
ABML at $.07, which you can read here.
The fact is that there is always a bull market somewhere. That’s why it’s important for penny stock investors to trade both OTC and NASDAQ stocks, and sometimes get exposure to larger companies that still seem to have massive growth potential. There are always opportunities if you give yourself the flexibility to trade all markets.
If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.
We also recommend you own a portfolio of hot stocks. For some, that can be as many as 10 to 20 or more stocks. This provides diversification and allows one to manage the market’s moods much easier.
In this article, we take a look at 4 hot stocks today, of which one is listed on NASDAQ and one is traded on the NYSE American. They are Aterian, Inc (NASDAQ: ATER), Health Revenue Assurance Holdings, Inc (OTCPK: HRAA), aTyr Pharma, Inc (NASDAQ: LIFE), and PHI Group, Inc (OTCPK: PHIL).
Hot Stocks #1 ATER
Aterian, Inc has been surging about 200% over the last month despite the correction on Tuesday that wiped out 40%. You can buy ATER for $10.96 per share, up from $3.12 on August 23, when the stock touched the lowest level since June last year.
ATER is a good short squeeze candidate with almost 30% of the float being shorted. ATER is benefiting from a surging interest in meme stocks, although it’s not the most popular candidate in this group.
All in all, the recent rally hasn’t been driven by any major news related to the company or external factors. It’s just that retail traders show more interest in ATER as a short squeeze candidate. As recent history has shown with stocks like GameStop, retail investors have become a force when they get together on social media. They are capable of dethroning hedge funds that manage billions.
With 30% of float still consisting of shorts, ATER may continue to rally. While trading meme stocks are riskier, ATER has just touched the lowest in over a year and may find enough strength to rebound to recent swing highs.
$ATER was just $20 not to long ago so why shouldn’t it bounce right back? I’m in for a solid swing.
— The Barter Guy (@barter_better) September 8, 2021
More importantly, trading volumes surged to record highs during ATER’s rally, with over 240 million shares changing hands on Monday alone, while the average volume figure had previously fluctuated between 400k and 3 million.
Meanwhile, ATER has some solid business and reported an increase in revenue and income during Q2. The company operates a technology-enabled consumer products business in North America and internationally. It provides Artificial Intelligence Mohawk e-Commerce Engine, a software technology platform that employs machine learning, natural language processing, and data analytics to design, develop, market, and sell products.
The company’s platform provides home and kitchen appliances, kitchenware, heating, cooling, and health and beauty products, as well as air quality appliances, such as dehumidifiers, humidifiers, and air conditioners under the hOmeLabs, Vremi, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, and Spiralizer brands. It also sells essential oils.
We think you should keep an eye on this meme stock candidate as the short interest maintains high. If you are interested in screening for meme stocks and finding the next Gamestop, check out our article here.
Hot Stocks #2 HRAA
Health Revenue Assurance Holdings, Inc is a Pink Current stock that has been on the rise. The $18 million company saw its share price surging by over 700% during the last five days, bringing the year-to-date gain at over 1,500%. You can buy HRAA for $0.33. Rallies like this prove why penny stocks are worth trading and subscribing to Insider Financial.
The stock has been getting attention because it’s led by David Lazar, who is known for taking over shells and then finding merger candidates that bring value to shareholders.
Last week, the company reported a private transaction during which 10 million shares of HRAA Series A-1 preferred stock of $0.001 par value per share were transferred from Custodian Ventures, LLC to AmeriGuard Security Services, Inc. Thus, AmeriGuard becomes holders of about 91% of the voting rights of the issued and outstanding HRAA shares, effectively taking control over the controlling shareholders.
AmeriGuard is a security company with over 500 employees and over $100 million annual revenue. Now, this is huge for a tiny shell firm with only a $20 million market cap. Its client list includes corporate giants like General Electric and PG&E Company, as well as government agencies, including Federal Court House in San Francisco, Federal Aviation Administration Oakland ARTCC in Fremont, Homeland Security, and more.
$HRAA Late EOD push 🔥 PR can drop anytime of Reverse merger with AmeriGuard Security Services. A 21 year old company with 500-1000+ employees and govt contracts potential btwn $50-$100M looking to go public for expansion. pic.twitter.com/ihNJqqCGjP
— Game Blouses (@TiredPops) September 15, 2021
As a result of the deal, David Lazar ceased to be the company’s CEO, CFO, president, treasurer, secretary, and director. He has been replaced by AmeriGuard CEO Lawrence Garcia.
We think HRAA is a great buy, and when the official news of the reverse merger is announced, it will surge even higher. As we said in Monday’s video, always book profits if you catch a move like HRAA and if you missed the move, wait for the dip like we just got.
Hot Stocks #3 LIFE
Nasdaq-listed aTyr Pharma, Inc has been consistently ascending during the last few months, but the bullish mood has intensified this week, with the share price doubling from Monday to Tuesday to hit a 2+ year high at $11.90, before correcting to the current level of $8.52. The surge in volume has been impressive, to say the least, as over 210 million shares changed hands on Monday and Tuesday, while the volume indicator used to fluctuate between 100k and 500k for most of the time.
LIFE is a clinical-stage biotherapeutics company that engages in the discovery and development of medicines based on novel immunological pathways in the US. Its main clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. The product is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis.
LIFE is also developing ATYR2810, a fully-humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers.
Earlier this week, the company announced positive results from its phase Ib/IIa double-blind, placebo-controlled study of its lead candidate, ATYR1923, for pulmonary sarcoidosis, which is an inflammatory disease characterized by the formulation of granulomas, clumps of inflammatory cells, in one or more organs of the body.
The primary objective of the study was to evaluate the safety, tolerability, immunogenicity, and pharmacokinetic profile of multiple doses of ATYR1923 compared to placebo. Results showed that ATYR1923 was safe and well-tolerated at all doses without any drug-related serious adverse events or signal of immunogenicity.
The study was conducted with its Hong Kong subsidiary, Pangu BioPharma Limited, which supports basic and translational research in tRNA synthetase biology.
Paul Schimmel, Ph.D., Professor of Molecular Medicine at The Scripps Research Institute and Founder of aTyr and Pangu, stated:
“We are very pleased to be a part of this groundbreaking work for ATYR1923, which represents the first clinical proof-of-concept for a tRNA synthetase derived therapy. The consistent dose response and clinically meaningful benefit observed across key efficacy endpoints is quite notable.”
LIFE plans to share its data with the FDA.
Robert Baughman, M.D., Professor of Medicine and Pulmonologist at the University of Cincinnati Medical Center, said:
“I am very impressed by this study, which is one of the best that I have seen conducted in sarcoidosis, a patient population that is highly underserved by current treatment options.”
Following the announcement, HC Wainwright & Co. analyst Joseph Pantginis maintained its BUY rating for LIFE and raised the price target from $13 to $18. Elsewhere, Oppenheimer analyst Hartaj Singh raised the price target from $14 to $20.
So what else can be said?
Dips in LIFE are seen as discount entry opportunities before the inevitable run to $20.
Hot Stocks #4 PHIL
PHI Group, Inc is a Pink Current stock that’s set to provide great value to shareholders. At the time of writing, it is trading at $0.090 – a bargain price that may soon go higher without looking back. The share price peaked at the end of June at almost two pennies, after which it corrected until mid-August. PHIL has gained over 20% since last week and is ready to break the YTD high.
PHIL has got the Pink Current status quite recently and is currently acting as a merger and acquisition firm. It targets select industries and special situations. The company also provides M&A advisory and consulting services to domestic and international clients through its wholly-owned subsidiary PHI Capital Holdings, Inc.
Besides this, PHIL’s subsidiaries include American Pacific Resources, Inc, Abundant Farms, Inc, PHI EZ Water Tech, Inc, PHI Group Regional Center, LLC, PHIVITAE Corporation, PHI EU International, S.R.L., ComMatrix, Inc, American Pacific Plastics, Inc, and Pacific FinTech Corporation.
PHIL started its recent bullish trend last week when the company said that its CEO had acquired more shares, and it would release some major news. On September 14, PHIL said that it had reached an agreement to acquire Five Grain Treasure Spirits Co – a 100-year old company that supplies to Kweichow Moutai Co. Details of the transaction will be announced in an upcoming press release.
$PHIL We have reached an agreement to acquire Five Grain Treasure Spirits Co., a 100-year old company that supplies to Kweichow Moutai Co.(https://t.co/nuTT1n0pPU). Details of the transaction will be announced in an upcoming press release and discussed in a conference call. GB!
— PHI GROUP INC (@PHIGROUP) September 14, 2021
Kweichow Moutai is the world’s largest liquor supplier, with a market cap of about $400 billion. The Chinese liquor maker’s main business is the production and commercialization of premium Moutai and Baijiu spirits. Moutai is one of the most expensive drinks in China.
We reported on PHIL in May of this year, when the penny stock was trading at $0.004. The company has had some ups and downs since then, and now it’s time for it to make investors happy.
THE FINAL NOTE
Now is a great opportunity to invest in hot stocks with great potential. Our job is to identify the best stock alerts with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio oriented at penny stocks.
The 4 stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the stock market. Still, whenever a hot stock is in the middle of a bull run, we recommend our subscribers to book profits.
It’s very important to eye stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of stocks to buy each week, trying to find the best alerts for our subscribers.
Remember, all you need is one or two stocks to run in order to crush the market averages.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.